575 related articles for article (PubMed ID: 25452114)
21. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
Lassen A; Atefi M; Robert L; Wong DJ; Cerniglia M; Comin-Anduix B; Ribas A
Mol Cancer; 2014 Apr; 13():83. PubMed ID: 24735930
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
Kim KB; Kefford R; Pavlick AC; Infante JR; Ribas A; Sosman JA; Fecher LA; Millward M; McArthur GA; Hwu P; Gonzalez R; Ott PA; Long GV; Gardner OS; Ouellet D; Xu Y; DeMarini DJ; Le NT; Patel K; Lewis KD
J Clin Oncol; 2013 Feb; 31(4):482-9. PubMed ID: 23248257
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF
Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM
Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444
[TBL] [Abstract][Full Text] [Related]
24. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected
Hauschild A; Dummer R; Schadendorf D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Haas T; Shilkrut M; Gasal E; Kefford R; Kirkwood JM; Long GV
J Clin Oncol; 2018 Dec; 36(35):3441-3449. PubMed ID: 30343620
[TBL] [Abstract][Full Text] [Related]
25. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
26. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
Algazi AP; Othus M; Daud AI; Lo RS; Mehnert JM; Truong TG; Conry R; Kendra K; Doolittle GC; Clark JI; Messino MJ; Moore DF; Lao C; Faller BA; Govindarajan R; Harker-Murray A; Dreisbach L; Moon J; Grossmann KF; Ribas A
Nat Med; 2020 Oct; 26(10):1564-1568. PubMed ID: 33020646
[TBL] [Abstract][Full Text] [Related]
27. Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma.
Takahashi A; Namikawa K; Nakano E; Yamazaki N
J Dermatol; 2020 Mar; 47(3):257-264. PubMed ID: 31876308
[TBL] [Abstract][Full Text] [Related]
28. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
[TBL] [Abstract][Full Text] [Related]
29. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.
Matter-Walstra K; Braun R; Kolb C; Ademi Z; Dummer R; Pestalozzi BC; Schwenkglenks M
Br J Dermatol; 2015 Dec; 173(6):1462-70. PubMed ID: 26332527
[TBL] [Abstract][Full Text] [Related]
30. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
Corcoran RB; Atreya CE; Falchook GS; Kwak EL; Ryan DP; Bendell JC; Hamid O; Messersmith WA; Daud A; Kurzrock R; Pierobon M; Sun P; Cunningham E; Little S; Orford K; Motwani M; Bai Y; Patel K; Venook AP; Kopetz S
J Clin Oncol; 2015 Dec; 33(34):4023-31. PubMed ID: 26392102
[TBL] [Abstract][Full Text] [Related]
31. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
[TBL] [Abstract][Full Text] [Related]
32. Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.
Carlino MS; Fung C; Shahheydari H; Todd JR; Boyd SC; Irvine M; Nagrial AM; Scolyer RA; Kefford RF; Long GV; Rizos H
Clin Cancer Res; 2015 Jan; 21(1):98-105. PubMed ID: 25370473
[TBL] [Abstract][Full Text] [Related]
33. Interaction of molecular alterations with immune response in melanoma.
Szczepaniak Sloane RA; Gopalakrishnan V; Reddy SM; Zhang X; Reuben A; Wargo JA
Cancer; 2017 Jun; 123(S11):2130-2142. PubMed ID: 28543700
[TBL] [Abstract][Full Text] [Related]
34. First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma.
Kim CG; Kim M; Hwang J; Kim ST; Jung M; Kim KH; Kim KH; Chang JS; Koom WS; Roh MR; Chung KY; Kim TM; Kim SK; Lee J; Shin SJ
J Am Acad Dermatol; 2022 Nov; 87(5):989-996. PubMed ID: 36068115
[TBL] [Abstract][Full Text] [Related]
35. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
Ascierto PA; Ferrucci PF; Fisher R; Del Vecchio M; Atkinson V; Schmidt H; Schachter J; Queirolo P; Long GV; Di Giacomo AM; Svane IM; Lotem M; Bar-Sela G; Couture F; Mookerjee B; Ghori R; Ibrahim N; Moreno BH; Ribas A
Nat Med; 2019 Jun; 25(6):941-946. PubMed ID: 31171878
[TBL] [Abstract][Full Text] [Related]
36. Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.
Atkinson V; Long GV; Menzies AM; McArthur G; Carlino MS; Millward M; Roberts-Thomson R; Brady B; Kefford R; Haydon A; Cebon J
Asia Pac J Clin Oncol; 2016 Dec; 12 Suppl 7():5-12. PubMed ID: 27905182
[TBL] [Abstract][Full Text] [Related]
37. Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life.
Prescrire Int; 2016 Dec; 25(177):285-288. PubMed ID: 30758923
[TBL] [Abstract][Full Text] [Related]
38. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.
Johnson AS; Crandall H; Dahlman K; Kelley MC
J Am Coll Surg; 2015 Apr; 220(4):581-93.e1. PubMed ID: 25797743
[TBL] [Abstract][Full Text] [Related]
39. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.
Duggan MC; Stiff AR; Bainazar M; Regan K; Olaverria Salavaggione GN; Maharry S; Blachly JS; Krischak M; Walker CJ; Latchana N; Tridandapani S; de la Chapelle A; Eisfeld AK; Carson WE
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9629-9634. PubMed ID: 28827320
[TBL] [Abstract][Full Text] [Related]
40. Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma.
Cocorocchio E; Pala L; Battaglia A; Gandini S; Peccatori FA; Ferrucci PF
Acta Oncol; 2018 Aug; 57(8):1131-1133. PubMed ID: 29526130
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
